Abstract
A knowledge of the causes and risk factors of fatal infection in childhood lupus nephritis (LN) patients treated with intravenous cyclophosphamide (IVCY) is important to enable optimal treatment. During an 11-year period (1996–2007), severe infection cases occurred in 31/84 (36.9%) patients with 64 infection episodes in our central referral institution in southern Thailand. Fatal infections occurred in 13/31 (41.9%) patients, most (11/13, 84.6%) during the first infective episode. The major causative organisms of the fatal infections were fungus and Gram-negative bacilli. Fatal infections were more likely to occur in patients with a prior history of treatment with pulse methylprednisolone and in patients with more active LN, as evidenced by the higher proteinuria and serum creatinine levels and lower hemoglobin and lymphocyte counts in this group than in patients with non-fatal infections. Multivariate analysis indicated that factors associated with fatal infection were prior treatment with pulse methylprednisolone [odds ratio (OR) 11.2, 95% confidence interval (CI) 1.9–61.0], renal failure (OR 5.9, 95% CI 1.0–34.8), and fungal infection (OR 23.9, 95% CI 1.9–298.2). Cases of active LN treated with IVCY and pulse methylprednisolone who later develop severe infection that fails to respond to antibiotics should be carefully investigated for fungal infection.
Similar content being viewed by others
References
Austin HA 3rd, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH, Decker JL (1986) Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 314:614–619
Lehman TJ, Onel K (2000) Intermittent intravenous cyclophosphamide arrests progression of the renal chronicity index in childhood systemic lupus erythematosus. J Pediatr 136:243–247
Gonzalez B, Hernandez P, Olguin H, Miranda M, Lira L, Toso M, Quezada A, Norambuena X, Talesnik E, Mendez C, Navarrete C (2005) Changes in the survival of patients with systemic lupus erythematosus in childhood: 30 years experience in Chile. Lupus 14:918–923
Kang I, Park SH (2003) Infectious complications in SLE after immunosuppressive therapies. Curr Opin Rheumatol 15:528–534
Duffy KN, Duffy CM, Gladman DD (1991) Infection and disease activity in systemic lupus erythematosus: a review of hospitalized patients. J Rheumatol 18:1180–1184
Hellmann DB, Petri M, Whiting-O’Keefe Q (1987) Fatal infections in systemic lupus erythematosus: the role of opportunistic organisms. Medicine (Baltimore) 66:341–348
Bosch X, Guilabert A, Pallares L, Cerveral R, Ramos-Casals M, Bove A, Ingelmo M, Font J (2006) Infections in systemic lupus erythematosus: a prospective and controlled study of 110 patients. Lupus 15:584–589
Pryor BD, Bologna SG, Kahl LE (1996) Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus. Arthritis Rheum 39:1475–1482
Chen YS, Yang YH, Lin YT, Chiang BL (2004) Risk of infection in hospitalized children with systemic lupus erythematosus: a 10-year follow-up. Clin Rheumatol 23:235–238
Ng WL, Chu CM, Wu AK, Cheng VC, Yuen KY (2006) Lymphopenia at presentation is associated with increased risk of infections in patients with systemic lupus erythematosus. QJM 99:37–47
Pattaragarn A, Sumboonnanonda A, Parichatikanond P, Supavekin S, Suntornpoch V, Vongjirad A (2005) Systemic lupus erythematosus in Thai children: clinicopathologic findings and outcome in 82 patients. J Med Assoc Thai 88(Suppl 8):S232–S241
Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, Aydintug AO, Jedryka-Goral A, de Ramon E, Fernandez-Nebro A, Galeazzi M, Haga HJ, Mathieu A, Houssiau F, Ruiz-Irastorza G, Ingelmo M, Hughes GR (1999) Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 78:167–175
Abu-Shakra M, Urowitz MB, Gladman DD, Gough J (1995) Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J Rheumatol 22:1259–1264
Kim WU, Min JK, Lee SH, Park SH, Cho CS, Kim HY (1999) Causes of death in Korean patients with systemic lupus erythematosus: a single center retrospective study. Clin Exp Rheumatol 17:539–545
Ward MM, Pyun E, Studenski S (1995) Causes of death in systemic lupus erythematosus. Long-term followup of an inception cohort. Arthritis Rheum 38:1492–1499
Janwityanuchit S, Totemchokchyakarn K, Krachangwongchai K, Vatanasuk M (1993) Infection in systemic lupus erythematosus. J Med Assoc Thai 7:542–548
Opastirakul S, Chartapisak W (2005) Infection in children with lupus nephritis receiving pulse and oral cyclophosphamide therapy. Pediatr Nephrol 20:1750–1755
Houssiau FA, Vasconcelos C, D’Cruz D, Sebastiani GD, Garrido Ed Ede R, Danieli MG, Abramovicz D, Blockmans D, Mathieu A, Direskeneli H, Galeazzi M, Gul A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R (2002) Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 46:2121–2131
Noel V, Lortholary O, Casassus P, Cohen P, Genereau T, Andre MH, Mouthon L, Guillevin L (2001) Risk factors and prognostic influence of infection in a single cohort of 87 adults with systemic lupus erythematosus. Ann Rheum Dis 60:1141–1144
Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725
Vachvanichsanong P, Dissaneewate P, Winn T (2004) Intravenous cyclophosphamide for lupus nephritis in Thai children. Scand J Rheumatol 33:339–342
King CK, Glass R, Bresee JS, Duggan C (2003) Managing acute Gastroenteritis among children: oral rehydration, maintenance, and nutritional therapy. MMWR Recomm Rep 52(RR-16):1–16
Tranaeus A, Heimburger O, Lindholm B (1989) Peritonitis in continuous ambulatory peritoneal dialysis (CAPD): diagnostic findings, therapeutic outcome and complications. Perit Dial Int 9:179–190
Gladman DD, Hussain F, Ibanez D, Urowitz MB (2002) The nature and outcome of infection in systemic lupus erythematosus. Lupus 11:234–239
Tsao CH, Chen CY, Ou LS, Huang JL (2002) Risk factors of mortality for Salmonella infection in systemic lupus erythematosus. J Rheumatol 29:1214–1218
Shahram F, Akbarian M, Davatchi F (1993) Salmonella infection in systemic lupus erythematosus. Lupus 2:55–59
Berenguer J, Buck M, Witebsky F, Stock F, Pizzo PA, Walsh TJ (1993) Lysis centrifugation blood cultures in the detection of tissue-proven invasive candidiasis. Disseminated versus single-organ infection. Diagn Microbiol Infect Dis 17:103–109
Ward MM, Donald F (1999) Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality. Arthritis Rheum 42:780–789
Mok CC, Yuen KY, Lau CS (1997) Nocardiosis in systemic lupus erythematosus. Semin Arthritis Rheum 26:675–683
Leong KP, Tee NW, Yap WM, Chee TS, Koh ET (2000) Nocardiosis in patients with systemic lupus erythematosus. The Singapore Lupus Study Group. J Rheumatol 27:1306–1312
Mora CS, Segami MI, Hidalgo JA (2006) Strongyloides stercoralis hyperinfection in systemic lupus erythematosus and the antiphospholipid syndrome. Semin Arthritis Rheum 36:135–143
Livneh A, Coman EA, Cho SH, Lipstein-Kresch E (1988) Strongyloides stercoralis hyperinfection mimicking systemic lupus erythematosus flare. Arthritis Rheum 31:930–931
Scowden EB, Schaffner W, Stone WJ (1978) Overwhelming strongyloidiasis: an unappreciated opportunistic infection. Medicine (Baltimore) 57:527–544
Laoprasopwattana K, Pruekprasert P, Laosombat V, Wongchanchailert M (2007) Clinical outcome of febrile neutropenia in children with cancer using ceftazidime and aminoglycosides. Pediatr Hematol Oncol 24:595–606
Hsu CL, Chen KY, Yeh PS, Hsu YL, Chang HT, Shau WY, Yu CL, Yang PC (2005) Outcome and prognostic factors in critically ill patients with systemic lupus erythematosus: a retrospective study. Crit Care 9:R177–R183
Williams FM, Chinn S, Hughes GR, Leach RM (2002) Critical illness in systemic lupus erythematosus and the antiphospholipid syndrome. Ann Rheum Dis 61:414–421
Levy M, Montes de Oca M, Claude-Babron M (1994) Unfavorable outcomes (end-stage renal failure/death) in childhood onset systemic lupus erythematosus. A multicenter study in Paris and its environs. Clin Exp Rheumatol 12(Suppl 10):S63–S68
Whitelaw DA, Gopal R, Freeman V (2005) Survival of patients with SLE admitted to an intensive care unit-a retrospective study. Clin Rheumatol 24:223–227
Wallace DJ, Podell T, Weiner J, Klinenberg JR, Forouzesh S, Dubois EL (1981) Systemic lupus erythematosus-survival patterns. Experience with 609 patients. JAMA 245:934–938
Manger K, Manger B, Repp R, Geisselbrecht M, Geiger A, Pfahlberg A, Harrer T, Kalden JR (2002) Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus. Ann Rheum Dis 61:1065–1070
Mok CC, Lee KW, Ho CT, Lau CS, Wong RW (2000) A prospective study of survival and prognostic indicators of systemic lupus erythematosus in a southern Chinese population. Rheumatology (Oxford) 39:399–406
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Laoprasopwattana, K., Dissaneewate, P. & Vachvanichsanong, P. Fatal infection in children with lupus nephritis treated with intravenous cyclophosphamide. Pediatr Nephrol 24, 1337–1343 (2009). https://doi.org/10.1007/s00467-009-1152-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00467-009-1152-7